Exploring the structure-activity relationships of [1-(4-(4- tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective δ-opioid receptor nonpeptide agonist ligand

Journal of Medicinal Chemistry

Volumn 42, Issue 26, 1999, Pages 5359-5368

  Alfaro Lopez, Josue ^a,c   Okayama, Toru ^a   Hosohata, Keiko ^b   Davis, Peg ^b   Porreca, Frank ^b   Yamamura, Henry I ^b   Hruby, Victor J ^a  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 TERT BUTYL 3' HYDROXYBENZHYDRYL) 2,4 DIBENZYLPIPERAZINE; 1 BENZYL 4 (4 TERT BUTYL 3' HYDROXYBENZHYDRYL)PIPERAZINE; OPIATE RECEPTOR AFFECTING AGENT; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; MALE; MOUSE; NONHUMAN; PHARMACOPHORE; RAT; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZHYDRYL COMPOUNDS; BRAIN; GUINEA PIGS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; MUSCLE, SMOOTH; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033620015     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990337f     Document Type: Article

References (41)

1. Rapaka, R. S.; Porreca, F. Development of Delta Opioid Peptides as Non-Addicting Analgesics. Pharmacol. Res. 1991, 8, 1-8.
2. (a) Mosberg, H. I.; Hrust, R.; Hruby, V. J.; Gee, K.; Yamamura, H. I.; Burks, T. F. Bis-Penicillamine Enkephalins Possess Highly Improved Specificity Toward Delta Opioid Receptors. Proc. Natl. Acad. Sci. U.S.A 1983, 80, 5871-5874.
3. 5]enkephalin. Life Sci. 1989, 45, 1001-1008.
4. 5]-Enkephalin: A Selective and High Affinity Radioligand for δ-Opioid Receptors With Extraordinary Specific Activity. J. Pharm. Exp. Ther. 1991, 258, 1077-1083.
5. 5]enkephalin and Two Halogenated Analogues After Intravenous Administration. J. Pharm. Exp. Ther. 1991, 259, 1109-1117.
6. (a) Sawyer, T. K. Peptidomimetic Design and Chemical Approaches to Peptide Metabolism. In Peptide-Based Drug Design. Controlling Transport and Metabolism; Taylor, M. D., Ed.; American Chemical Society: Washington, D.C., 1995; pp 388-422.
7. (b) Wiley, R. A.; Rich, D. A. Peptidomimetics Derived from Natural Products. Med. Res. Rev. 1993, 13, 327-384.
8. (c) Gante, J. Peptidomimetics-Tailored Enzyme Inhibitors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699-1720.
9. Hruby, V. J.; Yamamura, H. I.; Porreca, F. Molecular Organization of Receptors: Efficacy, Agonist and Antagonists. Ann. N.Y. Acad. Sci. 1995, 757, 7-22.
10. Liao, S.; Alfaro-Lopez, J.; Shenderovich, M. D.; Hosohata, K.; Yamamura, H. I.; Hruby, V. J. De Novo Design, Synthesis and Biological Activities of High Affinity and Selective Non-Peptide Agonists of the δ-Opioid Receptor. J. Med. Chem. 1998, 41, 4767-4776.
11. Qian, X.; Shenderovich, M. D.; Kover, K. E.; Hruby, V. J. Probing the Stereochemical Requirements for Receptor Recognition of δ-Opioid Agonists Through Topographic Modifications in Position 1. J. Am. Chem. Soc. 1996, 118, 7280-7290.
12. (a) Calderon, S. N.; Rothman, R. B.; Porreca, F.; Fillipen-Andersen, J. L.; Rice, K. C. Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(aR)-α(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]N, Ndiethylbenzamide (SNC80): A Highly Selective, Non-Peptide δ-Opioid Receptor Agonist. J. Med. Chem. 1994, 37, 2125-2130.
13. (b) Knapp, R. J.; Santoro, G.; De Leon, I.; Lee, K. B.; Edsall, S. A.; Waite, S.; Malatynska, E.; Varga, E.; Calderon, S. N.; Rice, K. N.; Rothman, R. B.; Porreca, F.; Roeske, W. R.; Yamamura, H. Y. Structure-Activity Relationships for SNC80 and Related Compounds at Cloned Human Delta and Mu Opioid Receptors. J. Pharm. Exp. Ther. 1996, 277, 1284-1291.
14. Qian, X.; Liao, S.; Hruby, V. J. Novel Scaffolds for Non-Peptide Mimetics of δ-Opioid Receptor Agonists Based on Peptide Leads. Regul. Pept. 1996, 65, 79-82.
15. (a) Ertan, M.; Tayhan, A. B.; Yulug, N. Synthesis and Antimicrobial Activities of Some New Tetrahydro-2H-1,3,5-thiadiazine-2-thione Derivatives of Ampicillin. Arch. Pharm. (Weinheim, Ger.) 1990, 323, 605-609.
16. (b) Ertan, M.; Ayyildiz, H. G.; Yulug, N. Synthesis and Antifungal Activities of Some New Tetrahydro-2H-1,3,5-thiadiazine-2-thiones. Arzneim.-Forsch. / Drug Res. 1991, 41, 1182-1185.
17. (c) Ertan, M. Synthesis and Antifungal Activities of Some 3-(2-Phenylethyl)-5-substituted-tetrahydro-2H-1,3,5-thiadiazine-2-thiones. Arzneim.-Forsch. / Drug Res. 1992, 42, 160-163.
18. (d) Ilhan, E. Synthesis and Antimicrobial Activity of New Tetrahydro-2H-1,3,5-thiadiazine-2-thione Derivatives. Il Farmaco 1995, 50, 787-790.
19. 1 Opioid Receptor Agonists and Antagonists. J. Med. Chem. 1993, 36, 2572-2574.
20. Farmer, P. S. Binding the Gap Between Bioactive Peptides and Non-Peptides: Some Perspectives in Design. In Drug Design; Ariens, E. J., Ed.; Academic Press: New York, 1980; Vol. X, p 127.
21. (a) Falorni, M.; Taddei, M. A New Diketopiperazine Tetra-Carboxylic Acid Template for the Homogeneous Phase Synthesis of Chemical Libraries. Tetrahedron Lett. 1997, 38, 4663-4666.
22. (b) Gordon, D. W.; Steele, J. Reductive Alkylation on a Solid-Phase: Synthesis of Piperazinedione Combinatorial Library. Bioorg. Med. Chem. Lett. 1995, 5, 47-50.
23. (c) Kowalski, J.; Lipton, M. A. Solid-Phase Synthesis of a Diketopiperazine Catalyst Containing the Unnatural Amino Acid (S)-Norarginine. Tetrahedron Lett. 1996, 37, 5839-5840.
24. (d) Scott, B. O.; Spear, K. L. Solid-Phase Organic Synthesis (SPOS): A Novel Route to Diketopiperazines and Diketomorpholines. Mol. Diversity 1995, 1, 125-134.
25. Duncan, R. L., Jr.; Helsey, G. C.; Welstead, W. J.; Lunsfard, C. D. Aroylpiperidines and Pyrrolidines. A New Class of Potent Central Nervous Depressants. J. Med. Chem. 1970, 13, 1-6.
26. Casy, A. F.; Dewar, G. H.; Pascoe, R. A. Opioid Properties of Some Derivatives of Phetidine Tropane. J. Pharm. Pharmacol. 1992, 44, 787-790.
27. Kaiser, E.; Colesscott, R. L.; Bassinger, C. D. Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides. Anal. Biochem. 1970, 34, 595-598.
28. Pohlmann, A. Efficient Synthesis of Conformationally Constrained Peptidomimetics Containing 2-Oxopiperazines. J. Org. Chem. 1997, 62, 1016-1022.
29. Kramer, T. H.; Davies, P.; Hruby, V. J.; Porreca, F. In Vitro Potency, Affinity and Agonist Efficacy of Highly Selective Delta Opioid Receptor Ligands. J. Pharm. Exp. Ther. 1993, 266, 577-584.
30. (a) Chang, K. J.; Rigdon, G. C.; Howard, G. L. A Novel, Potent and Selective Non-Peptide δ-Opioid Receptor Agonist BW373U86. J. Pharm. Exp. Ther. 1993, 267, 852-855.
31. (b) Nagase, H.; Wakita, K.; Matsura, H.; Takezawa, Y. Synthesis of Non-Peptidic Delta Opioid Agonists and Their SAR Relationships. Jpn. J. Pharmacol. 1994, 64, 35-40.
32. (c) Knapp, R. J.; Landsman, R.; Waite, S.; Varga, E.; Hruby, V. J.; Yamamura, H. I. Properties of TAN-67, A Non-Peptidic δ-Opioid Receptor Agonist at the Cloned Human δ- and μ-Opioid Receptor. Eur. J. Pharmacol. 1995, 291, 129-134.
33. (d) Dondio, G.; Ronzoni, S.; Eggleston, D. S. Discovery of a Novel Class of Substituted Pyrrolooctahydroisoquinolines as Potent and Selective δ Opioid Agonists, Based on an Extension of the Message-Address Concept. J. Med. Chem. 1997, 40, 3192-3198.
34. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-Peptide δ Opioid Agonists and Antagonists (Part II). Exp. Opin. Ther. Patents 1999, 9, 353-374.
35. Jorgensen, W. L.; Tirado-Rives, J. The OPLS Potential Functions for Proteins. Energy Minimizations for Crystals of Cyclic Peptides and Crambin. J. Am. Chem. Soc. 1988, 110, 1657-1666.
36. Monte Carlo simulations were done using MacroModel version 6.0 (Department of Chemistry, Columbia University, New York).
37. Portoghese, P. S.; Sultana, M.; Nagase, H. Application of the Message-Address Concept in the Design of Highly Potent and Selective Non-Peptide δ-Opioid Receptor Antagonists. J. Med. Chem. 1988, 31, 281-282.
38. a) Hruby, V. J.; Li, G.; Haskell-Luevano, C. Design of Peptides, Proteins and Peptidomimetics in Chi Space. Biopolymers 1997, 43, 219-266.
39. (b) Liao, S.; Han, Y.; Qiu, W.; Bruck, M.; Hruby, V. J. Synthesis of Highly Constrained β-Aryl Isohexanoic Acid Derivatives Via Asymmetric Michael Addition. Tetrahedron Lett. 1996, 37, 7917-7920.
40. Carroll, F. I.; Ferguson, A. M.; Lewis, J. H. Studies Concerning the Cyclization of Some 4-Bromoacetylpiperidines to the Corresponding 3-Quinuclidinones. J. Org. Chem. 1966, 31, 2957-2962.
41. Gilligan, P. J.; Cain, G. A.; Christor, T. E.; Cook, L. Novel Piperidine σ Receptor Ligands as Potential Antipsychotic Drugs. J. Med. Chem. 1992, 35, 4344-4361.